Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Public Health
84%
Malaria Vaccine
84%
Infection
76%
Malaria Control
73%
Chemoprophylaxis
60%
Diseases
58%
Prevalence
47%
Health Care Cost
42%
COVID-19
35%
Severe Acute Respiratory Syndrome Coronavirus 2
32%
Plasmodium falciparum
29%
Cost-Effectiveness Analysis
24%
Monoclonal Antibody
23%
Malaria Falciparum
22%
Mass Immunization
21%
Antimalarial Agent
21%
Sulfadoxine/Pyrimethamine
21%
Antimalarial
20%
Health System
20%
Non-Pharmaceutical Intervention
13%
Omicron Coronavirus Variant
13%
Medical Intervention
13%
Cohort Effect
12%
Plasmodium
12%
COVID-19 Vaccine
12%
Health Outcomes
12%
Pharmacokinetics
11%
Vaccination Coverage
11%
Booster Dose
11%
Mathematical Analysis
10%
Drug Administration
10%
Drug Interaction
10%
Long-Lasting Insecticidal Net
10%
Pyrethroid
10%
Antivirus Agent
10%
Life Cycle
10%
Drug Efficacy
10%
Phase III Trials
10%
Remote Sensing
10%
Malaria
10%
Drug Resistance
10%
Case Management
10%
High Risk Population
9%
Bite
9%
Comorbidity
8%
Host Parasite Interaction
7%
Combination Therapy
6%
Vector Control
6%
Disease Burden
6%
Dormancy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malaria Vaccine
96%
Pharmacokinetics
95%
Diseases
74%
Prevalence
64%
Elimination
56%
Infection
55%
Malaria Falciparum
48%
Plasmodium falciparum
43%
Antimalarial Agent
42%
Tribendimidine
31%
Amidantel
29%
Physiologically Based Pharmacokinetic Modelling
25%
Parasite Prevalence
24%
Amodiaquine
24%
Opisthorchis viverrini
23%
Artemisinin
21%
Drug Development
21%
Pyrimethamine Plus Sulfadoxine
21%
Clinical Trial
16%
Combination Therapy
14%
Opisthorchiasis
13%
Pharmacokinetic Parameter
13%
Tablet
12%
Drug Action
11%
Repurposing
10%
Case Fatality Rate
10%
Drug-Drug Interaction
10%
Drug Administration
10%
Plasmodium vivax
10%
Pharmacokinetic Modeling
10%
Parasite Clearance
10%
Antivirus Agent
10%
Naphthoquine
10%
Malaria
10%
Vaccine Efficacy
10%
Volume of Distribution
9%
Plasmodium
7%
Combination Vaccine
7%
Drug Resistance
7%
HIV
6%
Preclinical Study
5%
Drug Discovery
5%
SARS Coronavirus
5%
Administered Dose
5%
Comorbidity
5%
Immunology and Microbiology
Dynamics
100%
Infection
94%
Plasmodium falciparum
85%
Malaria Control
57%
RTS,S
52%
Prevalence
46%
Plasmodium vivax
31%
Disease Burden
24%
Scale up
23%
Antimalarial Agent
22%
Rabies
21%
Monoclonal Antibody
21%
Plasmodium
18%
Booster Dose
17%
Sporozoite
14%
Drug Efficacy
12%
Parasitemia
11%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Omicron Coronavirus Variant
10%
Influenza
10%
Parasite Clearance
10%
Water Bird
10%
Developmental Stage
10%
Incubation Time
10%
Epidemiological Data
10%
Aves
10%
Immunology
10%
Drug Resistance
10%
COVID-19
10%
Parasite Transmission
10%
All Cause Mortality
10%
High Risk Population
10%
Parasite Prevalence
9%
Cohort Effect
9%
Drug Screening
8%
Rabies Transmission
7%
Rebound
7%
Highly Pathogenic Avian Influenza Virus
7%
Immunoreactivity
7%
Humoral Immunity
7%
Virus
7%
Host Parasite Interaction
7%
Vaccine Efficacy
6%
Drug Mechanism
6%
Immune Response
6%
Disability-Adjusted Life Year
5%
Dormancy
5%
Influenza A Virus (H5N1)
5%
Insecticide Resistance
5%
Breakthrough Infection
5%